Lannett And FDA To Meet Over Insulin Glargine Biosimilar

Follow-On To Lantus Being Developed With China’s HEC Pharm

 
• By Dean Rudge
  
Lantus
Lannett has ambitious goals to become a $1bn company, fuelled by launches like biosimilar Lantus • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products